These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 27423978)

  • 1. The state and consequences of dermatology drug prices in the United States.
    Albrecht J; Lebwohl M; Asgari MM; Bennett DD; Cook A; Evans CC; Green LJ; Hodge JA; Kourosh AS; Maloney ME; Howard LM; Olsen EA; Rosenberg SP; Rubin A; Stough DB; Taylor SC; Brod BA
    J Am Acad Dermatol; 2016 Sep; 75(3):603-605. PubMed ID: 27423978
    [No Abstract]   [Full Text] [Related]  

  • 2. Dissecting drug pricing: Supply chain, market, and nonmarket trends impacting clinical dermatology.
    Nguyen HP; Go JA; Barbieri JS; Stough D; Stoff BK; Forman HP; Bolognia JL; Albrecht J;
    J Am Acad Dermatol; 2020 Aug; 83(2):691-699. PubMed ID: 32330637
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-31. PubMed ID: 28252884
    [No Abstract]   [Full Text] [Related]  

  • 4. Generic drugs--safe, effective, and affordable.
    Peters JR; Hixon DR; Conner DP; Davit BM; Catterson DM; Parise CM
    Dermatol Ther; 2009; 22(3):229-40. PubMed ID: 19453347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic consequences of underuse of generic drugs: evidence from Medicaid and implications for prescription drug benefit plans.
    Fischer MA; Avorn J
    Health Serv Res; 2003 Aug; 38(4):1051-63. PubMed ID: 12968816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic grand rounds: the economics of the new medicare drug benefit: implications for people with mental illnesses.
    Donohue JM
    Psychiatr Serv; 2005 Jun; 56(6):645-7. PubMed ID: 15939937
    [No Abstract]   [Full Text] [Related]  

  • 7. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generic drugs in dermatology: part II.
    Payette M; Grant-Kels JM
    J Am Acad Dermatol; 2012 Mar; 66(3):353.e1-15; quiz 367-8. PubMed ID: 22342022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaceuticals and Medical Devices: Medicare Part D.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-31. PubMed ID: 28252885
    [No Abstract]   [Full Text] [Related]  

  • 10. Value-Based Pricing and State Reform of Prescription Drug Costs.
    Hwang TJ; Kesselheim AS; Sarpatwari A
    JAMA; 2017 Aug; 318(7):609-610. PubMed ID: 28692713
    [No Abstract]   [Full Text] [Related]  

  • 11. Controlling pharmacy costs in the NC Medicaid program.
    Dobson LA
    N C Med J; 2003; 64(6):280-2. PubMed ID: 14983617
    [No Abstract]   [Full Text] [Related]  

  • 12. Medicaid prescription drug coverage: state efforts to control costs.
    Gencarelli DM
    NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic drugs in dermatology: part I.
    Payette M; Grant-Kels JM
    J Am Acad Dermatol; 2012 Mar; 66(3):343.e1-8; quiz 351-2. PubMed ID: 22342021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Policy Recommendations for Pharmacy Benefit Managers to Stem the Escalating Costs of Prescription Drugs: A Position Paper From the American College of Physicians.
    Daniel H; Bornstein SS;
    Ann Intern Med; 2019 Dec; 171(11):823-824. PubMed ID: 31711103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reference pricing for drugs: is it compatible with U.S. health care?
    Kanavos P; Reinhardt U
    Health Aff (Millwood); 2003; 22(3):16-30. PubMed ID: 12757268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What a Food and Drug lawyer should know about the Medicare Modernization Act.
    Azar AM
    Food Drug Law J; 2004; 59(2):217-22. PubMed ID: 15318393
    [No Abstract]   [Full Text] [Related]  

  • 17. Prior authorizations for dermatologic medications: An American Academy of Dermatology survey of US dermatology providers and staff.
    Secrest AM; Asgari MM; Kourosh AS; Barbieri JS; Albrecht J;
    J Am Acad Dermatol; 2017 Oct; 77(4):784-786. PubMed ID: 28917469
    [No Abstract]   [Full Text] [Related]  

  • 18. State Medicaid prescription drug expenditures for Medicare-Medicaid dual eligibles: estimates of Medicaid savings and federal expenditures resulting from expanded Medicare prescription coverage.
    Dale SB; Verdier JM
    Issue Brief (Commonw Fund); 2003 Apr; (627):1-12. PubMed ID: 12685428
    [No Abstract]   [Full Text] [Related]  

  • 19. Changes in PBM Business Practices in 2019: True Innovation or More of the Same?
    Motheral BR; Fairman KA
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1325-1333. PubMed ID: 32869706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing generic drug use in Medicare Part D: the role of government.
    Kohl H; Shrank WH
    J Am Geriatr Soc; 2007 Jul; 55(7):1106-9. PubMed ID: 17608887
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.